David W. Ellison

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma

  Neuro-Oncology · 2026-05-01

• Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer

  Cancer Discovery · 2026-04-19

• Advancing CNS tumor diagnostics with expanded DNA methylation-based classification

  Cancer Cell · 2025-12-04 · 18 citations

• Central Nervous System Kinase‐Altered Spindle Cell Neoplasm: A Case Series of an Emerging Tumour Type

  Neuropathology and Applied Neurobiology · 2025-12-01

• PTHP-15. Enhancing Medulloblastoma Classification: Integrating IHC and DNA Methylation Data from the SJMB12 Clinical Trial

  Neuro-Oncology · 2025-11-01

• EXTH-74. Nuclear Transport as a Therapeutic Vulnerability in ZFTA-RELA Ependymoma

  Neuro-Oncology · 2025-11-01

• PTHP-02. The clinical value of histopathological and molecular metrics in pediatric ependymoma - data from the ACNS0831 trial

  Neuro-Oncology · 2025-11-01 · 1 citations

• TMOD-14. Synthetic ZFTA-fusions pinpoint IDR acquisition as a mechanism of brain tumor development

  Neuro-Oncology · 2025-11-01

• Figure S7 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Table S1 and S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S18 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S9 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S17 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S20 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S22 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S3 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S13 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S16 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02

• Figure S21 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

  2025-09-02